Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Personalis shows promise in cancer detection but is years away from profitability. Read why PSNL stock is rated a hold with ...

Jennifer Doudna, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold a portion of her holdings in the company. According to a recent SEC filing, Doudna sold 1,320 shares of Tempus AI's Class A ...

Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), sold 6,059 shares of the company's Class A ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Improve AI model performance for lung cancer diagnostics: Leverage Tempus' real-world data to continuously refine Imagene's lung AI models, ensuring cutting-edge accuracy and effectiveness in ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...